863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
M Gross-Goupil,T G Kwon,Masatoshi Eto,D. Ye,H Miyake,S. I Seo,S S Byun,Jong Lyul Lee,Viraj A. Master,J Jin,R Debenedetto,R Linke,Michelle Casey,Brad Rosbrook,M J Lechuga Frean,Olga Valota,E Grande,David I. Quinn
DOI: https://doi.org/10.1093/annonc/mdy283
IF: 51.769
2018-01-01
Annals of Oncology
Abstract:Background: Axitinib (AXI) is approved for second-line treatment of advanced RCC. This Phase 3, randomized, double-blind trial compared the efficacy and safety of adjuvant AXI vs placebo (PBO) in patients (pts) at high risk of recurrent RCC. Methods: Pts had undergone nephrectomy; >50% clear-cell RCC; no evidence of macroscopic residual or metastatic disease (independent review committee [IRC] confirmed). The intent-to-treat (ITT) population (pop) was all randomized pts ≥pT2 and/or N1 with any Fuhrman grade (FG) and ECOG PS 0-1. Pts (stratified by risk group and country) received (1:1) oral AXI 5 mg twice daily (BID) or PBO for up to 3 y, with min 1 y until recurrence, evidence of a second primary malignancy, significant toxicity, or consent withdrawal. Max dose increases to 10 mg BID and decreases to 1 mg BID were allowed. The primary endpoint was disease-free survival (DFS; IRC). Secondary endpoints were overall survival (OS) and safety. Results: 724 pts were included: 363 AXI and 361 PBO. Most pts were Asian (73.3%), median age 58.0 y and highest risk (56.5%; defined as pT3 with FG ≥ 3 or pT4 and/or N1 with any FG). The study was stopped due to futility at a preplanned interim analysis at 203 DFS (IRC) events. DFS in the ITT pop and highest and lower risk subpops are shown in the table. OS data were not mature (deaths: 7.7% AXI and 7.2% PBO). Median (range) treatment duration was 19.9 (0.1-37.0) mo for AXI and 21.9 (0.0-36.9) mo for PBO. More adverse events (AEs; 98.6% vs 92.5%), serious AEs (19.4% vs 14.5%), grade 3-4 AEs (61.2% vs 30.1%), dose reductions (56.2% vs 8.4%), interruptions (51.4% vs 21.7%) and discontinuations due to AEs (23.3% vs 11.1%) were reported for AXI vs PBO. The most common AE was hypertension: 64.3% and 24.5%, respectively.Table: 863OSummary of disease-free survivalITT popaAxitinib (N = 363)Placebo (N = 361)Based on IRCMedian (95% CI), yNR (4.1-NR)NR (4.1-NR)HR (95% CI)0.870 (0.660-1.147)P value0.3211Based on investigator assessmentMedian (95% CI), yNR (3.6-NR)NR (4.1-NR)HR (95% CI)0.776 (0.599-1.005)P value0.0536Highest risk popbAxitinib (N = 209)Placebo (N = 200)Based on IRCMedian (95% CI), yNR (3.5-NR)NR (2.5-NR)HR (95% CI)0.735 (0.525-1.028)P value0.0704Based on investigator assessmentMedian (95% CI), y4.4 (3.4-NR)2.8 (1.5-NR)HR (95% CI)0.641 (0.468-0.879)P value0.0051Lower risk popbAxitinib (N = 146)Placebo (N = 149)Based on IRCMedian (95% CI), yNR (NR-NR)NR (NR-NR)HR (95% CI)1.016 (0.620-1.666)P value0.9483Based on investigator assessmentMedian (95% CI), yNR (NR-NR)NR (NR-NR)HR (95% CI)1.048 (0.654-1.681)P value0.8445CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Score; HR, hazard ratio; IRC, independent review committee; ITT, intent-to-treat; NR, not reached aHR and its CIs are obtained from the Cox proportional hazards model stratified by risk group. Two-sided P values based on the log-rank test stratified by risk group. bHR and its CIs are obtained from an unstratified Cox proportional hazards model. Two-sided P values based on an unstratified log-rank test. ITT pop included all randomized pts ≥pT2 and/or N1 with any Fuhrman grade and ECOG PS 0-1. The highest risk pop had pT3 with Fuhrman grade ≥3 or pT4 and/or N1 with any Fuhrman grade. The lower risk pop had pT2 or pT3 with Fuhrman grade ≤2. Open table in a new tab CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Score; HR, hazard ratio; IRC, independent review committee; ITT, intent-to-treat; NR, not reached aHR and its CIs are obtained from the Cox proportional hazards model stratified by risk group. Two-sided P values based on the log-rank test stratified by risk group. bHR and its CIs are obtained from an unstratified Cox proportional hazards model. Two-sided P values based on an unstratified log-rank test. ITT pop included all randomized pts ≥pT2 and/or N1 with any Fuhrman grade and ECOG PS 0-1. The highest risk pop had pT3 with Fuhrman grade ≥3 or pT4 and/or N1 with any Fuhrman grade. The lower risk pop had pT2 or pT3 with Fuhrman grade ≤2. Conclusions: In ATLAS, there were no significant differences between AXI and PBO for DFS in the ITT pop and lower risk subpop, whereas a significant difference for DFS per investigator was seen in the highest risk subpop. No new safety signals were seen in pts at high risk of recurrent RCC. Clinical trial identification: NCT01599754. Editorial acknowledgement: Medical writing support was provided by Anne Marie McGonigal, PhD, of Engage Scientific Solutions, and funded by Pfizer. Legal entity responsible for the study: SFJ Pharma and Pfizer. Funding: SFJ Pharma and Pfizer. Disclosure: M. Gross-Goupil: BMS, Ipsen, Novartis, Pfizer, Roche. R. Debenedetto, R. Linke: Employee of SFJ Pharmaceuticals. M. Casey, B. Rosbrook, M.J. Lechuga Frean, O. Valota: Employee of Pfizer Inc. E. Grande: Advisory board services and honoraria: Pfizer, BMS, Roche, EUSA Pharma, Astra Zeneca. D.I. Quinn: Advisory board services and honoraria: Pfizer, Bayer, Novartis, BMS, Merck, Exelixis, Genentech, Roche, Janssen, Astra Zeneca, Astellas. All other authors have declared no conflicts of interest.